Protagonist Therapeutics Inc (PTGX)
Protagonist Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing peptide-based and other targeted therapies. Its pipeline includes Icotyde, an investigational oral peptide being studied for moderate-to-severe plaque psoriasis in adults and adolescents aged 12 and older, and Rusfertide, an injectable hepcidin mimetic in Phase 3 development for polycythemia vera. The company is also advancing PN-881 for immune-mediated skin diseases, along with several earlier-stage programs in obesity, atopic dermatitis, asthma, and related conditions. Founded in 2006, Protagonist Therapeutics is headquartered in Newark, California, and its common stock trades on NASDAQ under the symbol PTGX.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PTGX
|
$91.56
|
-32.6% Downside
|
Overvalued
|
$125.15
|
-7.9% Downside
|
Fair
|
Good
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-76.1x
|
13.3x
|
117.8x
|
8.635 B
|
8.114 B
|
0.1%
|
81.6%
|
122.9
|
—
|
102.8%
|
